{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:30:50Z","timestamp":1787333450983,"version":"build-2736575974"},"reference-count":100,"publisher":"Elsevier","isbn-type":[{"value":"9780443470547","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.ai.2026.04.006","type":"book-chapter","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:28:11Z","timestamp":1778617691000},"page":"401-435","source":"Crossref","is-referenced-by-count":0,"title":["Neuroinflammation and vaccination strategy in Parkinson\u2019s disease"],"prefix":"10.1016","author":[{"family":"Yukti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanyukta","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ateendra Kumar","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay Kumar","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.ai.2026.04.006_bib1","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6564585","article-title":"Blood-brain barrier overview: Structural and functional correlation","volume":"2021","author":"Alahmari","year":"2021","journal-title":"Neural Plasticity"},{"issue":"1","key":"10.1016\/bs.ai.2026.04.006_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-024-12770-x","article-title":"An update on immune-based alpha-synuclein trials in Parkinson\u2019s disease","volume":"272","author":"Alfaidi","year":"2025","journal-title":"Journal of Neurology"},{"issue":"40","key":"10.1016\/bs.ai.2026.04.006_bib3","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M600933200","article-title":"Phosphorylation of Ser-129 is the dominant pathological modification of \u03b1-synuclein in familial and sporadic lewy body disease","volume":"281","author":"Anderson","year":"2006","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/bs.ai.2026.04.006_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.biocel.2008.06.010","article-title":"Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases","volume":"41","author":"Aggarwal","year":"2009","journal-title":"International Journal of Biochemistry & Cell Biology"},{"issue":"S3","key":"10.1016\/bs.ai.2026.04.006_bib5","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1002\/ana.10479","article-title":"Bioenergetic approaches for neuroprotection in Parkinson\u2019s disease","volume":"53","author":"Beal","year":"2003","journal-title":"Annals of Neurology"},{"issue":"Number 8","key":"10.1016\/bs.ai.2026.04.006_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/occmed\/kqm110","article-title":"Active and passive immunity, vaccine types, excipients and licensing","volume":"57","author":"Baxter","year":"2007","journal-title":"Occupational Medicine"},{"issue":"3","key":"10.1016\/bs.ai.2026.04.006_bib7","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000227906.99570.cc","article-title":"Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: A case-control study","volume":"67","author":"Bower","year":"2006","journal-title":"Neurology"},{"issue":"Number 1","key":"10.1016\/bs.ai.2026.04.006_bib8","article-title":"The role of Galectin-3 in \u03b1-synuclein-induced microglial activation","volume":"2","author":"Boza-Serrano","year":"2014","journal-title":"Acta Neuropathologica Communications"},{"issue":"2","key":"10.1016\/bs.ai.2026.04.006_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiology of Aging"},{"issue":"1","key":"10.1016\/bs.ai.2026.04.006_bib10","article-title":"Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease","volume":"119","author":"Brochard","year":"2009","journal-title":"Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/bs.ai.2026.04.006_bib11","first-page":"27","article-title":"Glucocorticosteroids: Current and future directions","volume":"173","author":"Barnes","year":"2016","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/bs.ai.2026.04.006_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrn2038","article-title":"Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms","volume":"8","author":"Block","year":"2007","journal-title":"Nature Reviews. Neuroscience"},{"issue":"8","key":"10.1016\/bs.ai.2026.04.006_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti\u2013\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Movement Disorders"},{"issue":"16","key":"10.1016\/bs.ai.2026.04.006_bib14","doi-asserted-by":"crossref","first-page":"8370","DOI":"10.3390\/ijms22168370","article-title":"Reviewing the significance of blood\u2013brain barrier disruption in multiple sclerosis pathogenesis and treatment","volume":"22","author":"Balasa","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"1\u20132","key":"10.1016\/bs.ai.2026.04.006_bib15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jneuroim.2010.08.011","article-title":"Blood\u2013brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE","volume":"229","author":"Bennett","year":"2010","journal-title":"Journal of Neuroimmunology"},{"issue":"1","key":"10.1016\/bs.ai.2026.04.006_bib16","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1326-5-42","article-title":"Fcy receptors are required for NF-kB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson\u2019s disease","volume":"5","author":"Cao","year":"2010","journal-title":"Molecular Neurodegeneration"},{"issue":"3","key":"10.1016\/bs.ai.2026.04.006_bib17","first-page":"178","article-title":"Nonsteroidal anti-inflammatory drug use and the risk of Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"44","author":"Cote","year":"2015","journal-title":"Neuroepidemiology"},{"issue":"Number 3","key":"10.1016\/bs.ai.2026.04.006_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2011.10.014","article-title":"Pathological correlates of gastrointestinal dysfunction in Parkinson\u2019s disease","volume":"46","author":"Cersosimo","year":"2012","journal-title":"Neurobiology of Disease"},{"issue":"4","key":"10.1016\/bs.ai.2026.04.006_bib19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.bbalip.2014.08.010","article-title":"Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance","volume":"1851","author":"Calder","year":"2015","journal-title":"Biochimica et Biophysica Acta (BBA) \u2013 Molecular and Cell Biology of Lipids"},{"issue":"1","key":"10.1016\/bs.ai.2026.04.006_bib20","doi-asserted-by":"crossref","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","article-title":"The blood\u2013brain barrier","volume":"7","author":"Daneman","year":"2015","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"4","key":"10.1016\/bs.ai.2026.04.006_bib21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/JPD-130230","article-title":"The role of oxidative stress in Parkinson\u2019s disease","volume":"3","author":"Dias","year":"2013","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"14","key":"10.1016\/bs.ai.2026.04.006_bib22","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/bs.ai.2026.04.006_bib23","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1038\/emboj.2012.170","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease: Molecular mechanisms and pathophysiological consequences","volume":"31","author":"Exner","year":"2012","journal-title":"EMBO Journal"},{"issue":"9","key":"10.1016\/bs.ai.2026.04.006_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03101-8","article-title":"Target engagement and immunogenicity of an active immunotherapeutic targeting pathological \u03b1-synuclein: A phase 1 placebo-controlled trial","volume":"30","author":"Eijsvogel","year":"2024","journal-title":"Nature Medicine"},{"issue":"9","key":"10.1016\/bs.ai.2026.04.006_bib25","article-title":"Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin-proteasome system and \u03b1-synuclein","volume":"102","author":"Fornai","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"28","key":"10.1016\/bs.ai.2026.04.006_bib26","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson\u2019s disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/bs.ai.2026.04.006_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2013.12.028","article-title":"Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human \u03b1-synuclein: Feasibility study","volume":"560","author":"Ghochikyan","year":"2014","journal-title":"Neuroscience Letters"},{"issue":"2","key":"10.1016\/bs.ai.2026.04.006_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/S0197-4580(02)00091-X","article-title":"Motor dysfunction and gliosis with preserved dopaminergic markers in human \u03b1-synuclein A30P transgenic mice","volume":"24","author":"Gomez-Isla","year":"2003","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/bs.ai.2026.04.006_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbi.2025.04.028","article-title":"Peripheral-central immune crosstalk in Parkinson\u2019s disease and its association with clinical severity","volume":"128","author":"Greenland","year":"2025","journal-title":"Brain, Behavior, and Immunity"},{"issue":"6","key":"10.1016\/bs.ai.2026.04.006_bib30","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","article-title":"Mechanisms underlying inflammation in neurodegeneration","volume":"140","author":"Glass","year":"2010","journal-title":"Cell"},{"issue":"5","key":"10.1016\/bs.ai.2026.04.006_bib31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00401-014-1345-4","article-title":"Inflammatory dysregulation of blood monocytes in Parkinson\u2019s disease patients","volume":"128","author":"Grozdanov","year":"2014","journal-title":"Acta Neuropathologica"},{"issue":"11","key":"10.1016\/bs.ai.2026.04.006_bib32","first-page":"653","article-title":"The role of regulatory T cells in Parkinson\u2019s disease","volume":"13","author":"Gendelman","year":"2017","journal-title":"Nature Reviews Neurology"},{"issue":"10","key":"10.1016\/bs.ai.2026.04.006_bib33","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.ai.2026.04.006_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2010.217","article-title":"Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of parkinson\u2019s disease","volume":"19","author":"Harms","year":"2011","journal-title":"Molecular Therapy"},{"issue":"Number 4","key":"10.1016\/bs.ai.2026.04.006_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-021-02268-5","article-title":"Periphery and brain, innate and adaptive immunity in Parkinson\u2019s disease","volume":"141","author":"Harms","year":"2021","journal-title":"Acta Neuropathologica"},{"issue":"4","key":"10.1016\/bs.ai.2026.04.006_bib36","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u2019s disease: A target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurology"},{"issue":"5","key":"10.1016\/bs.ai.2026.04.006_bib37","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209137","article-title":"Cinpanemab in early Parkinson disease","volume":"102","author":"Hutchison","year":"2024","journal-title":"Neurology"},{"issue":"33","key":"10.1016\/bs.ai.2026.04.006_bib38","article-title":"Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration","volume":"106","author":"Jang","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"10","key":"10.1016\/bs.ai.2026.04.006_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-synuclein monoclonal antibody, in patients with Parkinson disease: A randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurology"},{"issue":"1","key":"10.1016\/bs.ai.2026.04.006_bib40","article-title":"Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson\u2019s disease","volume":"10","author":"Krashia","year":"2019","journal-title":"Nature Communications"},{"issue":"2","key":"10.1016\/bs.ai.2026.04.006_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/ng0298-106","article-title":"Ala30Pro mutation in the gene encoding \u03b1-synuclein in Parkinson\u2019s disease","volume":"18","author":"Kr\u00fcger","year":"1998","journal-title":"Nature Genetics"},{"issue":"9996","key":"10.1016\/bs.ai.2026.04.006_bib42","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/bs.ai.2026.04.006_bib43","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annual Review of Immunology"},{"issue":"Number 2","key":"10.1016\/bs.ai.2026.04.006_bib44","doi-asserted-by":"crossref","DOI":"10.1007\/s12035-012-8267-8","article-title":"Inflammation and \u03b1-synuclein\u2019s prion-like behavior in Parkinson\u2019s disease--is there a link?","volume":"47","author":"Lema Tom\u00e9","year":"2013","journal-title":"Molecular Neurobiology"},{"issue":"Number 2","key":"10.1016\/bs.ai.2026.04.006_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresrev.2008.10.004","article-title":"Neurogliogenesis in the mature olfactory system: A possible protective role against infection and toxic dust","volume":"59","author":"Loseva","year":"2009","journal-title":"Brain Research Reviews"},{"key":"10.1016\/bs.ai.2026.04.006_bib46","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41467-020-15626-w","article-title":"\u03b1-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson\u2019s disease","volume":"11","author":"Lindestam Arlehamn","year":"2020","journal-title":"Nature Communications"},{"issue":"18","key":"10.1016\/bs.ai.2026.04.006_bib47","article-title":"Mice lacking all conventional MHC class II genes","volume":"96","author":"Madsen","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"Number 4","key":"10.1016\/bs.ai.2026.04.006_bib48","doi-asserted-by":"crossref","DOI":"10.3233\/JPD-150685","article-title":"The concept of prodromal Parkinson\u2019s disease","volume":"5","author":"Mahlknecht","year":"2015","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"1","key":"10.1016\/bs.ai.2026.04.006_bib49","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-015-0008-9","article-title":"Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy","volume":"10","author":"Mandler","year":"2015","journal-title":"Molecular Neurodegeneration"},{"issue":"6","key":"10.1016\/bs.ai.2026.04.006_bib50","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: Implications for Parkinson\u2019s disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathologica"},{"issue":"8","key":"10.1016\/bs.ai.2026.04.006_bib51","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.08-08-02804.1988","article-title":"Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal","volume":"8","author":"Maroteaux","year":"1988","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/bs.ai.2026.04.006_bib52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1742-2094-5-45","article-title":"TNF signaling inhibition in the CNS: Implications for normal brain function and neurodegenerative disease","volume":"5","author":"McCoy","year":"2008","journal-title":"Journal of Neuroinflammation"},{"issue":"8","key":"10.1016\/bs.ai.2026.04.006_bib53","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.38.8.1285","article-title":"Reactive microglia are positive for HLA-DR in the: Substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains","volume":"38","author":"McGeer","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/bs.ai.2026.04.006_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuro.2021.02.001","article-title":"Dose-related biphasic effect of the Parkinson\u2019s disease neurotoxin MPTP, on the spread, accumulation, and toxicity of \u03b1-synuclein","volume":"84","author":"Merghani","year":"2021","journal-title":"Neurotoxicology"},{"key":"10.1016\/bs.ai.2026.04.006_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2015.12.018","article-title":"Dynamic structural flexibility of \u03b1-synuclein","volume":"88","author":"Mor","year":"2016","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.ai.2026.04.006_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2016.07.010","article-title":"Motor symptoms in Parkinson\u2019s disease: A unified framework","volume":"68","author":"Moustafa","year":"2016","journal-title":"Neuroscience and Biobehavioral Reviews"},{"issue":"1","key":"10.1016\/bs.ai.2026.04.006_bib57","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-021-02381-5","article-title":"Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric \u03b1-synuclein accumulation in the brain and gut","volume":"143","author":"Nimmo","year":"2022","journal-title":"Acta Neuropathologica"},{"issue":"Number 7","key":"10.1016\/bs.ai.2026.04.006_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/humu.21277","article-title":"Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update","volume":"31","author":"Nuytemans","year":"2010","journal-title":"Human Mutation"},{"issue":"Number 4","key":"10.1016\/bs.ai.2026.04.006_bib59","doi-asserted-by":"crossref","DOI":"10.1111\/bph.13139","article-title":"Microglial M1\/M2 polarization and metabolic states","volume":"173","author":"Orihuela","year":"2016","journal-title":"British Journal of Pharmacology"},{"issue":"Number 12","key":"10.1016\/bs.ai.2026.04.006_bib60","doi-asserted-by":"crossref","DOI":"10.1097\/GIM.0b013e31815bf97c","article-title":"Genetics of Parkinson disease","volume":"9","author":"Pankratz","year":"2007","journal-title":"Genetics in Medicine"},{"issue":"1","key":"10.1016\/bs.ai.2026.04.006_bib61","doi-asserted-by":"crossref","DOI":"10.1111\/j.1471-4159.2009.06150.x","article-title":"On the mechanism of internalization of \u03b1-synuclein into microglia: Roles of ganglioside GM1 and lipid raft","volume":"110","author":"Park","year":"2009","journal-title":"Journal of Neurochemistry"},{"issue":"3","key":"10.1016\/bs.ai.2026.04.006_bib62","first-page":"217","article-title":"Systemic infections and inflammation affect chronic neurodegeneration","volume":"10","author":"Perry","year":"2010","journal-title":"Nature Reviews. Immunology"},{"issue":"17014","key":"10.1016\/bs.ai.2026.04.006_bib63","article-title":"Parkinson disease. Nature reviews disease primers","volume":"3","author":"Poewe","year":"2017","journal-title":"Nature Reviews Disease Primers"},{"issue":"3","key":"10.1016\/bs.ai.2026.04.006_bib64","doi-asserted-by":"crossref","DOI":"10.3233\/JPD-212594","article-title":"Safety and tolerability of active immunotherapy targeting \u03b1-synuclein with PD03A in patients with early Parkinson\u2019s disease: A randomized, placebo-controlled, phase 1 study","volume":"11","author":"Poewe","year":"2021","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"5321","key":"10.1016\/bs.ai.2026.04.006_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science (New York, N. Y.)"},{"issue":"Number 13","key":"10.1016\/bs.ai.2026.04.006_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Movement Disorders"},{"issue":"Number 6511","key":"10.1016\/bs.ai.2026.04.006_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay4014","article-title":"The science and medicine of human immunology","volume":"369","author":"Pulendran","year":"2020","journal-title":"Science"},{"issue":"11","key":"10.1016\/bs.ai.2026.04.006_bib68","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","article-title":"Aberrations in peripheral inflammatory cytokine levels in Parkinson disease","volume":"73","author":"Qin","year":"2016","journal-title":"JAMA Neurology"},{"issue":"11","key":"10.1016\/bs.ai.2026.04.006_bib69","article-title":"Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Ray Dorsey","year":"2018","journal-title":"The Lancet Neurology"},{"issue":"5","key":"10.1016\/bs.ai.2026.04.006_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020495","article-title":"Immunolocalization of influenza a virus and markers of inflammation in the human Parkinson\u2019s disease brain","volume":"6","author":"Rohn","year":"2011","journal-title":"PLoS One"},{"issue":"Number 4","key":"10.1016\/bs.ai.2026.04.006_bib71","doi-asserted-by":"crossref","DOI":"10.4161\/hv.28578","article-title":"Vaccination strategies for Parkinson disease: Induction of a swift attack or raising tolerance?","volume":"10","author":"Romero-Ramos","year":"2014","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"6301","key":"10.1016\/bs.ai.2026.04.006_bib72","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1126\/science.aag2590","article-title":"How neuroinflammation contributes to neurodegeneration","volume":"353","author":"Ransohoff","year":"2016","journal-title":"Science (New York, N. Y.)"},{"issue":"Number 7","key":"10.1016\/bs.ai.2026.04.006_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease","volume":"18","author":"Schapira","year":"2017","journal-title":"Nature Reviews Neuroscience"},{"issue":"20","key":"10.1016\/bs.ai.2026.04.006_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.09.007","article-title":"Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes","volume":"184","author":"Scheiblich","year":"2021","journal-title":"Cell"},{"key":"10.1016\/bs.ai.2026.04.006_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01695","article-title":"Differentiation and transmigration of CD4 T cells in neuroinflammation and autoimmunity","volume":"8","author":"Sonar","year":"2017","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"10.1016\/bs.ai.2026.04.006_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/eji.200939975","article-title":"CXCR3 blockade inhibits T-cell migration into the CNS during EAE and prevents development of adoptively transferred, but not actively induced, disease","volume":"40","author":"Sporici","year":"2010","journal-title":"European Journal of Immunology"},{"key":"10.1016\/bs.ai.2026.04.006_bib77","doi-asserted-by":"crossref","DOI":"10.3233\/JPD-223237","article-title":"Microglia in Parkinson\u2019s disease","volume":"12","author":"Stefanova","year":"2022","journal-title":"Journal of Parkinson\u2019s Disease"},{"key":"10.1016\/bs.ai.2026.04.006_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.769506","article-title":"Alpha-synuclein induced immune cells activation and associated therapy in Parkinson\u2019s disease","volume":"13","author":"Su","year":"2021","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"12","key":"10.1016\/bs.ai.2026.04.006_bib79","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-022-11258-w","article-title":"Dysregulation of peripheral monocytes and pro-inflammation of alpha-synuclein in Parkinson\u2019s disease","volume":"269","author":"Su","year":"2022","journal-title":"Journal of Neurology"},{"issue":"Number 19","key":"10.1016\/bs.ai.2026.04.006_bib80","doi-asserted-by":"crossref","DOI":"10.1111\/febs.14607","article-title":"Determinants of dopaminergic neuron loss in Parkinson\u2019s disease","volume":"285","author":"Surmeier","year":"2018","journal-title":"FEBS Journal"},{"key":"10.1016\/bs.ai.2026.04.006_bib81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood\u2013brain barrier breakdown in neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nature Reviews Neurology"},{"issue":"1","key":"10.1016\/bs.ai.2026.04.006_bib82","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.stem.2018.06.015","article-title":"Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson\u2019s disease","volume":"23","author":"Sommer","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/bs.ai.2026.04.006_bib83","first-page":"23","article-title":"Do Th17 lymphocytes and IL-17 contribute to Parkinson\u2019s disease?","volume":"14","author":"Storelli","year":"2019","journal-title":"Journal of Neuroimmune Pharmacology"},{"issue":"7660","key":"10.1016\/bs.ai.2026.04.006_bib84","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature22815","article-title":"T cells from patients with Parkinson\u2019s disease recognize \u03b1-synuclein peptides","volume":"546","author":"Sulzer","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/bs.ai.2026.04.006_bib85","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/ejn.14290","article-title":"Immune system responses in Parkinson\u2019s disease: Early and dynamic","volume":"49","author":"Tansey","year":"2019","journal-title":"European Journal of Neuroscience"},{"issue":"10","key":"10.1016\/bs.ai.2026.04.006_bib86","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"Interleukin-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"2","key":"10.1016\/bs.ai.2026.04.006_bib87","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s12035-014-9070-5","article-title":"Differential roles of microglia in neurodegenerative diseases","volume":"53","author":"Tang","year":"2016","journal-title":"Molecular Neurobiology"},{"issue":"7","key":"10.1016\/bs.ai.2026.04.006_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: A randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"The Lancet Neurology"},{"key":"10.1016\/bs.ai.2026.04.006_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2016.03.010","article-title":"The blood\u2013brain barrier in systemic inflammation","volume":"60","author":"Varatharaj","year":"2017","journal-title":"Brain, Behavior, and Immunity"},{"issue":"2","key":"10.1016\/bs.ai.2026.04.006_bib90","first-page":"115","article-title":"The neuroprotective potential of flavonoids: A multiplicity of effects","volume":"5","author":"Vauzour","year":"2010","journal-title":"Genes & Nutrition"},{"issue":"2","key":"10.1016\/bs.ai.2026.04.006_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2012.06.025","article-title":"Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein","volume":"237","author":"Watson","year":"2012","journal-title":"Experimental Neurology"},{"key":"10.1016\/bs.ai.2026.04.006_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.ai.2026.04.006_bib93","first-page":"181","article-title":"Inflammatory cytokine gene polymorphisms and the risk of Parkinson\u2019s disease","volume":"8","author":"Wahner","year":"2007","journal-title":"Neurogenetics"},{"issue":"1","key":"10.1016\/bs.ai.2026.04.006_bib94","article-title":"Prasinezumab slows motor progression in Parkinsons disease: beyond the clinical data","volume":"11","author":"Xiao","year":"2025","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"1","key":"10.1016\/bs.ai.2026.04.006_bib95","article-title":"Fine mapping of the HLA locus in Parkinson\u2019s disease in Europeans","volume":"7","author":"Yu","year":"2021","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"7","key":"10.1016\/bs.ai.2026.04.006_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/mds.29016","article-title":"A randomized first-in-human study with UB-312, a UBITh\u00ae \u03b1-synuclein peptide vaccine","volume":"37","author":"Yu","year":"2022","journal-title":"Movement Disorders"},{"issue":"2","key":"10.1016\/bs.ai.2026.04.006_bib97","doi-asserted-by":"crossref","DOI":"10.1002\/ana.10795","article-title":"The new mutation, E46K, of \u03b1-synuclein causes Parkinson and lewy body dementia","volume":"55","author":"Zarranz","year":"2004","journal-title":"Annals of Neurology"},{"issue":"11","key":"10.1016\/bs.ai.2026.04.006_bib98","doi-asserted-by":"crossref","DOI":"10.1002\/glia.20532","article-title":"Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein","volume":"55","author":"Zhang","year":"2007","journal-title":"Glia"},{"issue":"Number 5","key":"10.1016\/bs.ai.2026.04.006_bib99","doi-asserted-by":"crossref","DOI":"10.1007\/s00281-022-00947-3","article-title":"The immunology of Parkinson\u2019s disease","volume":"44","author":"Zhu","year":"2022","journal-title":"Seminars in Immunopathology"},{"issue":"1","key":"10.1016\/bs.ai.2026.04.006_bib100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1474-4422(23)00377-0","article-title":"Blood\u2013brain barrier dysfunction in multiple sclerosis: Causes, consequences, and therapeutic implications","volume":"23","author":"Zierfuss","year":"2024","journal-title":"The Lancet Neurology"}],"container-title":["Advances in Immunology","Microglial Advances in Neurodegenerative Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065277626000192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065277626000192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:01:44Z","timestamp":1787331704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065277626000192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443470547"],"references-count":100,"URL":"https:\/\/doi.org\/10.1016\/bs.ai.2026.04.006","relation":{},"ISSN":["0065-2776"],"issn-type":[{"value":"0065-2776","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}